Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Abstract Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that on...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Zehra Sucuoglu Isleyen, Jamshid Hamdard, Sedat Yildirim, Tolga Dogan, Selver Isik, Abdussamet Celebi, Burcu Belen Gulbagci, Nail Paksoy, Mutlu Dogan, Haci Mehmet Turk, Ahmet Bilici, Ali Murat Tatli, Sinem Akbas, Nedim Turan, Ilhan Hacibekiroglu, Gamze Gokoz Dogu, Adnan Aydiner, Ahmet Taner Sumbul, Serap Akyurek, Merih Yalciner, Ahmet Demirkazik, Pinar Gursoy, Musa Baris Aykan, Elif Sahin, İbrahim Karadag, Osman Kostek, Muhammed Muhiddin Er, Mehmet Artaç, Yakup Duzkopru, Dincer Aydin, Deniz Isik, Yusuf Karakas, Saadettin Kilickap, Cihan Erol, Bilgin Demir, Burak Civelek, Yakup Ergun, Muhammed Bulent Akinci, Izzet Dogan, Nuri Karadurmus, Perran Fulden Yumuk, Mehmet Ali Nahit Sendur
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2024-03-01
סדרה:	Scientific Reports
נושאים:	Oncogene-driven advanced non-small cell lung cancer De novo brain metastases Survival related parameters
גישה מקוונת:	https://doi.org/10.1038/s41598-024-56046-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!